HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trialPublications / 2nd April 2020 van Poelgeest e al – 2013 (view in PDF)
